[
  {
    "ts": null,
    "headline": "Transcript : Merck & Co., Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 04",
    "summary": "Presenter SpeechChristopher Schott Good afternoon, everybody. I'm Chris Schott from JPMorgan, and it's my pleasure to be introducing Merck today. From the company, we have Rob Davis, Chairman and",
    "url": "https://finnhub.io/api/news?id=f7255c3b41bc5d0db22992c2630d013737a34f7586d775557fbb4d9c7d34f2b1",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736796600,
      "headline": "Transcript : Merck & Co., Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 04",
      "id": 132390525,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Presenter SpeechChristopher Schott Good afternoon, everybody. I'm Chris Schott from JPMorgan, and it's my pleasure to be introducing Merck today. From the company, we have Rob Davis, Chairman and",
      "url": "https://finnhub.io/api/news?id=f7255c3b41bc5d0db22992c2630d013737a34f7586d775557fbb4d9c7d34f2b1"
    }
  },
  {
    "ts": null,
    "headline": "Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025",
    "summary": "The cancer therapeutics market is set to exceed $400 billion. Read why five pharmaceutical companies offer attractive opportunities for investors.",
    "url": "https://finnhub.io/api/news?id=5893587e5fa3e91a37b6975c5ceac34f7fc311555b4dc90278e6109cce22d835",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736791802,
      "headline": "Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025",
      "id": 132390023,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1886168184/image_1886168184.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "The cancer therapeutics market is set to exceed $400 billion. Read why five pharmaceutical companies offer attractive opportunities for investors.",
      "url": "https://finnhub.io/api/news?id=5893587e5fa3e91a37b6975c5ceac34f7fc311555b4dc90278e6109cce22d835"
    }
  },
  {
    "ts": null,
    "headline": "UnitedHealth, Caterpillar share gains contribute to Dow's 240-point climb",
    "summary": "UnitedHealth, Caterpillar share gains contribute to Dow's 240-point climb",
    "url": "https://finnhub.io/api/news?id=acefd6c62b5e03c69f1a52f64769dcd68743f1fbdf4f7407acb14bb7b9c5ad1f",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736773140,
      "headline": "UnitedHealth, Caterpillar share gains contribute to Dow's 240-point climb",
      "id": 132407804,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "UnitedHealth, Caterpillar share gains contribute to Dow's 240-point climb",
      "url": "https://finnhub.io/api/news?id=acefd6c62b5e03c69f1a52f64769dcd68743f1fbdf4f7407acb14bb7b9c5ad1f"
    }
  },
  {
    "ts": null,
    "headline": "Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.",
    "summary": "Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.",
    "url": "https://finnhub.io/api/news?id=37e2a928d2167d0048035cc98a3a4b5233aa2bc53c699711f8e55cded28f8379",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736765823,
      "headline": "Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.",
      "id": 132407688,
      "image": "",
      "related": "MRK",
      "source": "DowJones",
      "summary": "Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.",
      "url": "https://finnhub.io/api/news?id=37e2a928d2167d0048035cc98a3a4b5233aa2bc53c699711f8e55cded28f8379"
    }
  },
  {
    "ts": null,
    "headline": "Moderna Stock Sinks. It Disappoints With Covid-19 Vaccine Forecast.",
    "summary": "Moderna Stock Sinks. It Disappoints With Covid-19 Vaccine Forecast.",
    "url": "https://finnhub.io/api/news?id=44c01c4ecf944e20c0b970968332a9a6e5fb8c34c36254940acf3e25c43aa936",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736758260,
      "headline": "Moderna Stock Sinks. It Disappoints With Covid-19 Vaccine Forecast.",
      "id": 132408339,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Moderna Stock Sinks. It Disappoints With Covid-19 Vaccine Forecast.",
      "url": "https://finnhub.io/api/news?id=44c01c4ecf944e20c0b970968332a9a6e5fb8c34c36254940acf3e25c43aa936"
    }
  },
  {
    "ts": null,
    "headline": "Arcus: Excellent Pipeline And Collaborations, Cash Runway",
    "summary": "Invest in Arcus Biosciences for a strong buying opportunity with promising data, robust pipeline, and significant market potential, backed by Gilead's...",
    "url": "https://finnhub.io/api/news?id=848a488d0821d0bec225d35b36f33826b8880e54142c3d5c97299de29456c0d0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736755200,
      "headline": "Arcus: Excellent Pipeline And Collaborations, Cash Runway",
      "id": 132387280,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1972341389/image_1972341389.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Invest in Arcus Biosciences for a strong buying opportunity with promising data, robust pipeline, and significant market potential, backed by Gilead's...",
      "url": "https://finnhub.io/api/news?id=848a488d0821d0bec225d35b36f33826b8880e54142c3d5c97299de29456c0d0"
    }
  },
  {
    "ts": null,
    "headline": "SpringWorks: PDUFA Review Date Could Lead To Next Approved Pipeline Candidate",
    "summary": "SpringWorks has shown strong revenue growth with OGSIVEO, achieving a 23% increase from Q2 of 2024 to Q3 of 2024. See why I rate SWTX stock a strong buy.",
    "url": "https://finnhub.io/api/news?id=8a4833b7c0dbcdf2a59ef3d7d12e8877cadca798aa4e02c468e92d343c93357c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736747815,
      "headline": "SpringWorks: PDUFA Review Date Could Lead To Next Approved Pipeline Candidate",
      "id": 132386392,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2177260462/image_2177260462.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "SpringWorks has shown strong revenue growth with OGSIVEO, achieving a 23% increase from Q2 of 2024 to Q3 of 2024. See why I rate SWTX stock a strong buy.",
      "url": "https://finnhub.io/api/news?id=8a4833b7c0dbcdf2a59ef3d7d12e8877cadca798aa4e02c468e92d343c93357c"
    }
  }
]